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ta.2012.1Abstract Background: In cholesteatoma, there is lack of control over cell proliferation that is why
ectodermal tissue grows to be an epidermoid cyst. So cholesteatoma may be considered as cell
growth disorder but still the cause of this uncontrolled proliferation is unknown.
Objective: The aim of this study is to detect telomerase activity in cholesteatoma and meatal skin
(as a control) and its relation to the clinical ﬁndings and severity of the disease.
Patients and methods: Samples of cholesteatoma and meatal skin were obtained from 31 patients
during ear surgery. Telomerase activity was detected using polymerase chain reaction based on telo-
meric repeat ampliﬁcation protocol assay then collected data were statistically analyzed.
Results: Telomerase activity was positive in 17/31 (54.8%) of cholesteatoma samples and was
negative in all meatal skin samples. Signiﬁcant high rates of intraoperative ossicular erosion and
preoperative air bone gap more than 40 dB were associated with positive telomerase activity.
Conclusions: Telomerase activity may play a role in the hyperproliferative nature and uncon-
trolled aggressive growth pattern of cholesteatoma.
ª 2012 Egyptian Society of Ear, Nose, Throat and Allied Sciences.
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2.0011. Introduction
The proliferative capacity of normal somatic cells is limited by
gradual loss of tandem nucleotide repeat (TTAGGG), termed
telomeres at chromosomal ends because of an end replication.1
Telomeres cap the ends of linear chromosomes and are
essential for maintaining chromosome stability. In the major-
ity of human cells, because of the end replication problem that
affects DNA polymerase, telomere shortens 50–100 base pairs
per cell division.2 When telomere reaches critical short length,
they lose their function, and DNA damage checkpoints be-
come activated, with either arresting in the cell cycle or under-
going apoptosis.3 However, cancer cells have a unique ability
to turn on telomerase, an enzyme that elongates telomeres,ces. Production and hosting by Elsevier B.V. All rights reserved.
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to divide and survive indeﬁnitely.4 So, the enzyme telomerase
counteracts telomere loss in proliferating cell and extends its
capacity for replication.5 Telomerase is also capable of synthe-
sizing telomere ends de novo.6
In the last years, studies on telomerase inhibition increased.
In 2005, FDA approved GRN-163L use as telomerase inhibi-
tor in patients with chronic lymphatic leukemia. From then, its
use was tried for other neoplastic lesions.7
Cholesteatoma is characterized by the presence of keratiniz-
ing squamous epithelium in the middle ear cleft with hyperpro-
liferative feature.8 Surgical management is the primary
strategy used to treat and control the disease. Despite recent
surgical advances,9 high rates of recurrences are still pres-
ent,9,10 emphasizing the need for a better understanding of
molecular mechanisms underlying cholesteatoma growth and
recurrence.9
Not all ectodermal tissues which invade or remain as a ves-
tige in the mesenchymal tissue grow and become a cholestea-
toma and it is thought that in a normal human, such
ectodermal tissues are naturally eliminated as a result of
apoptosis.11 In cholesteatoma, there is lack of control over cell
proliferation that is why ectodermal tissue grows to be an epi-
dermoid cyst. For this reason, cholesteatoma may be consid-
ered as a cell growth disorder,12 but still the cause of this
uncontrolled proliferation is unknown.13 So, cholesteatoma
is considered a tumor-like growth in the middle ear.14
There is a controversy regarding the impact of telomerase
activities on cellular proliferation in cholesteatoma.15
The aim of this work is to detect telomerase activity in cho-
lesteatoma and meatal skin (as a control) and its relation with
clinical ﬁndings and severity of the disease.
2. Materials and methods
This study was performed at the Otorhinolaryngology, Head
and Neck Surgery department and Clinical Pathology depart-
ment, Zagazig University Hospitals from February 2008 to
December 2011 on 31 patients with cholesteatoma with pars
ﬂacida perforation. The patients were 18 males and 13 females
aged between 28 and 66 years (mean age, 38 years).
All patients were subjected to full history taking, general
and local examination including microscopic ear examination.
Audiological and radiological evaluations were conducted to
ensure the diagnosis and extent of the disease. Then routine
preoperative laboratory tests were done.
Samples of cholesteatoma and samples of skin of the deep
part of the bony external auditory canal (as a control) were ob-
tained from all patients during ear surgery. These samples were
stored in liquid nitrogen at 80 C until use for telomerase
activity assay.
2.1. Measurement of telomerase activity
Telomerase activity was measured by Telo TAGGG
telomerase PCR ELISAplus polymerase chain reaction-based
telomeric repeat ampliﬁcation protocol (TRAP) assay, ﬁrst
described by Kim et al.16 But, instead of radioactive nucleotide
labeling, biotinylated primers were used during the extension
reaction, thus enabling quantitative photometric detection
by a streptavidin-DIG-peroxidase immunoreaction. TeloTAGGG telomerase PCR ELISAplus was supplied from
Roche Molecular Biochemicals, Mannheim, Germany.
The TRAP assay is a two-step process in which the telome-
rase-mediated elongation products are subsequently ampliﬁed
by PCR to allow highly sensitive detection of telomerase activ-
ity. Some samples contain inhibitors of Taq DNA polymerase,
thus giving false negative results when analyzed for telomerase
activity. To overcome this problem, the internal standard pro-
vided with the Telo TAGGG telomerase PCR ELISAplus, is a
216 bp homologous standard that allows a clear detection of
Taq DNA polymerase inhibitors. In total, 10–20 lm-thick fro-
zen sections of each specimen were cut. Thin slices of frozen
tissue specimens were prepared on sterile petri dishes with sur-
gical disposable knife blades to obtain thin ﬂakes, immediately
lysed in 200 ll of ice-cold lysis buffer, incubated on ice for
30 min and centrifuged at 16,000g for 20 min at 4 C. Five
microliters of each sample was heat-inactivated by incubation
at 85 C for 10 min prior to TRAP assay to inactivate telome-
rase protein to produce negative controls. For ampliﬁcation;
25 ll of reaction mixture (biotinylated telomerase substrate
P1-TS, optimized anchor-primer P2, nucleotides and Taq
DNA polymerase) and 5 ll of the internal standard (216 bp
DNA) were added per tube (a) 1–3 ll sample volume
(corresponding to 0.5 lg/ll protein, which was measured by
Bradford method) and 1–3 ll negative controls; (b) 1 ll
control template; and (c) lysing reagent as a blank for control
template. The total volume was completed up to 50 ll with
nuclease-free water. The PCR conditions were 1 cycle for pri-
mer elongation (25 C, 20 min), 1 cycle for telomerase inactiva-
tion (94 C, 5 min), followed by ampliﬁcation in the form of 30
PCR cycles (94 C for 30 s, 50 C for 30 s, 72 C for 90 s and
72 C for 10 min). PCR cycling was carried out in Perkin
Elmer cycler 9700. For each 2.5 ll of the ampliﬁcation prod-
uct, 10 ll of denaturating reagent was added into two separate
tubes.
Hybridization buffer T (DIG-labeled detection probe com-
plementary to telomeric repeat sequences P3-T) was added to
one tube and Hybridization buffer IS (DIG-labeled detection
probe complementary to the internal standard P3-IS) was
added to the second tube. One hundred microliters of each
mixture was transferred into each well. After incubation
and washing, 100 ll of Anti-DIG-HRP working solution
(Polyclonal antibody from sheep, conjugated to horseradish
peroxidase) was added per well and incubated at room tem-
perature for 30 min. After washing, 100 ll TMP substrate
solutions were added and incubated at room temperature
for 20 min. To stop color development 100 ll stopping solu-
tion was added. The absorbance was measured at 450 nm
(with a reference wavelength of 690 nm). Samples were con-
sidered as telomerase-positive if the difference in absorbance
of the samples was higher than twofold the negative control
reading.
2.2. Statistical analysis
Clinical features such as age and sex of the patients, hearing
loss, and intraoperative ossicular bone erosion were reported
and prepared for statistical analysis.
All data were subjected to computerized statistical analysis
by using SPSS program (Statistical package for the Social Sci-
ence, version 10, Chicago, IL).
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tive variables. Fisher exact test was used to assess signiﬁcance.
Data were expressed as mean (x) ± standard deviation (SD)
for quantitative variables. Student’s ‘‘t’’ test was used to assess
signiﬁcance.
3. Results
Telomerase activity was found to be positive in 17 patients
(54.8%) and negative in 14 patients (45.2%) of cholesteatoma
samples, while telomerase activity was found to be negative in
all meatal skin samples.
Extracts from all telomerase negative samples gave a posi-
tive signal for the internal telomerase assay standard, exclud-
ing Taqman polymerase inhibition. The relation of
telomerase activity to the patient’s age and sex, which has been
found to be non signiﬁcant, is summarized in Table 1.
All the seventeen patients with positive Telomerase activity
were found to have ossicular erosion intraoperatively while
such ﬁnding was found in only 9 patients (64.2%) with nega-
tive telomerase activity and this difference was found to be sta-
tistically signiﬁcant. At the same time, 15 patients (88.2%)
with positive Telomerase activity were found to have air bone
gap more than 40 dB, however it was found in only 7 (50%)
patients with negative telomerase activity.
This difference was also statistically signiﬁcant. This
relation of telomerase activity with preoperative audiolometricTable 1 Association of telomerase activity in cholesteatoma
as regards age and sex.
Patients Telomerase activity
Positive Negative P (value)
No % No. %
17/31 54.8 14/31 45.2 0.6101a
Sex
Male 10 55.5 8 44.5 0.7913a
Female 7 53.8 6 46.2
Age 39.5 ± 10.4 38 ± 9.7 0.6835b
a Fisher exact test.
b Student’s ‘‘t’’ test.
Table 2 The relation of telomerase activity and clinical
features in cholesteatoma.
Clinical feature Telomerase activity
Positive Negative P* (value)
No. % No. %
Intraoperative ossicular erosion
Ossicular erosion (No. = 26) 17 65.4 9 34.6 0.0117**
No ossicular erosion (No. = 5) 0 0 5 100
Preoperative audiolometric results
ABG***more than 40 db(No. 22) 15 68.2 7 31.8 0.0438**
ABG***less than 40 db (No. 9) 2 22.2 7 77.8
* Fisher exact test.
** Signiﬁcant.
*** Air-bone gap.results and intraoperative ossicular erosion is summarized in
Table 2
4. Discussion
The activation of telomerase enzyme has been found to be a
necessary step for the immortal growth of human cancer cell.16
Telomerase is activated in 85–90% of human cancer.4
The natural history of entrapped epithelial tissue (choleste-
atoma pearl) in the middle ear cleft is unknown, some may dis-
appear spontaneously, some remain static and others
progressively enlarge to become cholesteatoma. The factors
that determine the fate of this entrapped epithelial tissue in
the middle ear cleft have not been detected.
Cholesteatoma is considered as a tumor-like growth in the
middle ear because it shows persistent hyperproliferation.8
Although various theories have been developed regarding the
cause of the disease, the basic mechanisms of cholesteatoma
formation have still not been fully characterized. Although
generally understood to be a benign process, cholesteatoma
exhibits several clinical aspects of tumors as destruction of
adjacent tissue, bone erosion, and frequent recurrences after
surgery.9,10
Some previous studies8,17 found that telomerase activity
was closely related to cellular proliferation in chronic hyper-
proliferating tissue such as cholesteatoma.
In our study, telomerase activity was positive in 54.8% of
cholesteatoma samples and none of meatal skin was positive,
suggesting that telomerase activity may have a role to play in
continuous cell proliferation and growth (expansion). This re-
sult was not surprising as several molecular markers of tumor
formation had been found in cholesteatoma e.g. upregulation
of matrix metalloproteinases, c-myc, and activation of
angiogenesis.9,18
Only few studies have been performed on telomerase activ-
ity in cholesteatoma. Kojima et al.18 reported that telomerase
was detected in acquired cholesteatoma at a low frequency
(one out of ﬁve), suggesting that telomerase activity is speciﬁc
for malignant tumors but not for cholesteatoma. Nevertheless,
the number of cholesteatoma samples in their study was very
small (only ﬁve cases). Also Kuczkowski et al.19 detected telo-
merase activity as low as 2 (8.7%) of 23 samples of cholesta-
toma, and Watabe-Rudolph et al.9 found telomerase activity
positive in 1 of 29 cholesteatoma samples (3.4%) but they dem-
onstrated that the telomere lengths were similar in cholestea-
toma and squamous cell carcinoma (SCC). They proposed
that the absence of telomerase activity limits the proliferative
capacity of cholesteatoma by induction of apoptosis. With re-
spect to this explanation Kuczkowski et al.19 assumed that the
absence of telomerase may lead to generation of dysfunctional
telomeres what in turn may impair the proliferative capacity of
cholesteatoma.
On the other hand, Lee et al.8 found that telomerase activ-
ity was positive in 21/40 cholesteatomas (52.9%) and absent in
the control group, but the telomerase activity in SCC in the
same study was lower (66.7%) than the high rate reported
by other studies. Goh et al.20 also found a higher expression
of telomerase activity in 77.3% of cholesteatoma cases.
Age and sex of the patients did not signiﬁcantly affect the
detection of telomerase activity in cholesteatoma samples of
our study. A ﬁnding that was also reported by Goh et al.20
and Lee et al.8
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toma samples of patients with more preoperative hearing loss
and patients with intraoperative ossicular erosion and this
agrees with the conclusion of study of Lee et al.8 who reported
that cellular proliferation was signiﬁcantly higher in cases
where the telomerase activity was positive. While a previous
study20 found that these relations were insigniﬁcant.
Our results support the suggestion that the expression of
telomerase may be related to the proliferative nature of choles-
teatoma. So telomerase activity may be one of the factors
responsible for the pathogenesis of cholesteatoma. The signif-
icant difference between cases with positive and negative telo-
merase activity in relation to ossicular erosion in our study
indicates that telomerase activity is not only related to cellular
proliferation but may also be related to the pathogenesis of
bone erosion associated with cholesteatoma.
As FDA approved GRN-163L use as a telomerase inhibitor
in patients with chronic lymphatic leukemia7, it is needed to
investigate if telomerase inhibitor can be used to limit the pro-
gress of cholesteatoma and decrease its recurrence rates.
5. Conclusion
Telomerase activity was detected in 54.8% of cholesteatoma
samples and not in adjacent skin. Expression of telomerase
was signiﬁcantly higher in patients with more preoperative
hearing loss and intraoperative ossicular erosion suggesting
that the telomerase activation may be closely linked to the
hyperproliferative nature of cholesteatoma as well as bone ero-
sion associated with it.
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